

## Brolucizumab

## Chemical Properties

CAS No. : 1531589-13-5

Formula:

Molecular Weight:

Storage: Store at low temperature  
Store at -20°C

Actual storage temperature shall be subject to the COA.

## Biological Description

Description	Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity ( $K_D = 1.05 \text{ pM}$ ). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Targets(IC50)	VEGFR
In vitro	Brolucizumab (2683 nM) inhibits VEGFR1 phosphorylation in VEGF-A112-induced U87MG human glioma cells and VEGFR2 phosphorylation in ZHE-483-2 GMECs. [1]
In vivo	Brolucizumab (15 mg/kg, intravenous injection, five days a week) was used to treat mSLK-KSHV xenografts and the tumor growth in vivo was observed. <b>Results:</b> Brolucizumab slowed the growth of mSLK-KSHV xenograft tumors. [2]

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481